The numbers came back wrong. Researchers at the University of New Mexico had been methodically working through preserved brain tissue, running the usual analyses on samples drawn from a cohort of donors spanning 2016 to 2024. What they found was not a trace signal or a statistical whisper. The human brain, it turned out, carries microplastic concentrations seven to thirty times higher than matched samples of liver or kidney from the same donors. And over those eight years, the cumulative burden rose by roughly fifty percent. In donors who had died with dementia, the loads were heaviest of all.
It is the kind of result that demands you sit with it for a moment before reaching for what it might mean. These are not particles drifting through a tissue incidentally. They are accumulating, preferentially, in the organ we can least afford to contaminate.
From the Bloodstream to the Brain
The mechanism has been worked out, at least partially, in animal models. Polystyrene nanoparticles given orally to mice were tracked by Kopatz and colleagues as they moved through the body. Within two hours, they had crossed the blood-brain barrier. The key was size: larger particles did not make it. Nanoscale ones did, acquiring a coating of proteins during transit that appears to function as a kind of biological passport, granting entry to a compartment that evolution spent hundreds of millions of years making nearly impenetrable. That coating, the biomolecular corona, is what lets them in.
The cardiovascular evidence arrived from a different direction but converged on the same alarm. Marfella and colleagues examined plaque removed from patients undergoing carotid endarterectomy, surgery to clear blocked arteries supplying blood to the brain. They found microplastics and nanoplastics lodged inside the atheromatous material itself. Patients whose plaque tested positive experienced a roughly fourfold increase in the composite risk of heart attack, stroke, or death over the following thirty-four weeks. As a new Perspective published today in the journal Brain Health notes with some deliberateness, stroke is a brain outcome. These are not separate problems.
“We are looking at an organ where the highest measured concentrations of microplastics meet the most consequential clinical endpoints in medicine,” says Dr. Julio Licinio, lead author of the Perspective and CEO of Genomic Press. “Cognition, mood, stroke, dementia. Treating this as a peripheral environmental concern, when the relevant peripheral organs carry less of the contaminant than the central one, has become difficult to defend.”
Ultra-Processed Food as a Delivery System
Where does the exposure come from? The answer is largely, and inconveniently, dinner. Ultra-processed foods now supply more than half of caloric intake in the United States, and they function as high-throughput vectors for microplastic exposure through multiple routes: packaging that leaches material during heating and storage, mechanical wear during industrial processing, and downstream contamination in manufacturing environments. The particles find their way in during manufacture and, apparently, stay.
The dietary connection runs deeper than delivery, though. Independent of any microplastic content, ultra-processed food consumption has been linked in large prospective cohorts to depression, anxiety, cognitive decline, stroke, and dementia. A meta-analysis of 385,541 participants found a fifty-three percent increase in the odds of common mental disorder symptoms among the heaviest consumers. UK Biobank data connect the same dietary pattern to elevated dementia risk. Data from the REGARDS cohort showed that a ten percent rise in relative ultra-processed food intake was associated with a sixteen percent increase in cognitive impairment risk and an eight percent increase in stroke risk, holding independently of whether participants followed Mediterranean, DASH, or MIND dietary guidelines. The dietary signal and the plastic signal may be, at least partly, the same signal.
“The boundary between physical and mental health has always been more administrative than biological,” says Dr. Nicholas Fabiano of the University of Ottawa Department of Psychiatry, a co-author on the Perspective. “Microplastics do not respect that boundary. The same particles that lodge in atheroma also reach the brain. The same dietary exposures that raise cardiovascular risk also raise risk for depression and dementia. We are looking at one problem with many clinical faces.”
A Removal Pathway Emerges
The field now has something it lacked a year ago: a plausible first intervention. Bornstein and colleagues at the University Hospital Carl Gustav Carus in Dresden reported that therapeutic apheresis, a blood-filtering technique already in clinical use for conditions including autoimmune disorders and lipid dysregulation, can extract material consistent with microplastic particles from human plasma. The infrastructure for this already exists in tertiary care centers around the world. It is not a new technology requiring regulatory approval from scratch; it is an established modality being asked a new question.
“We were initially surprised by what we observed,” says Dr. Stefan R. Bornstein of Technische Universität Dresden and King’s College London. “The fact that it appears to engage these particles in vivo opens a path that did not exist a year ago. The work now is to validate the signal against measurement standards the broader scientific community can agree on, and to develop scalable alternatives matched to polymer specificity, tissue compartment, and patient population.”
The caveat is substantial, and the researchers are candid about it. “What the field still lacks is the measurement infrastructure that would let us rank polymers by harm and confirm that interventions are working,” says Dr. Charlotte Steenblock, also of Technische Universität Dresden. “Without validated, reproducible, polymer-specific quantification, no removal strategy can be confirmed in the strict sense. That is not a weakness of the apheresis approach. It is a feature of a field operating ahead of its own analytical tools.” You cannot easily prove you have removed something you cannot yet reliably measure. The science of detection has not kept pace with the science of accumulation.
In April 2026, ARPA-H, the American health research agency modeled on DARPA, launched a program called STOMP, Systematic Targeting Of MicroPlastics, organized around exactly the three priorities the new Perspective identifies: build measurement tools capable of characterizing nanoscale particles in complex biological tissue, illuminate the mechanisms by which microplastics traffic through organs, and translate that knowledge into clinical removal. Meanwhile, microplastics have been identified within the intracellular compartment of human placenta, suggesting fetal exposure during the developmental window when the blood-brain barrier is most permeable. Children, with higher per-kilogram intake than adults, are accumulating a lifetime burden whose trajectory today’s adult cohort data cannot fully predict.
In the absence of a validated removal strategy, the Perspective’s most immediate practical conclusion is also its most mundane: population-scale exposure reduction is currently achievable mainly by reducing ultra-processed food consumption. That is not a satisfying answer for a field that has just established that the brain preferentially concentrates a contaminant now linked to dementia and stroke. But it may be the one lever large enough to move in time to matter, while researchers work out whether apheresis can be refined, scaled, and eventually replaced by something more targeted still.
Source: doi.org/10.61373/bh026p.0006
Frequently Asked Questions
Is the brain really more contaminated with microplastics than other organs?
Based on the most comprehensive human tissue data available, yes. Researchers at the University of New Mexico found microplastic concentrations in brain samples seven to thirty times higher than in matched liver or kidney samples from the same donors, with the heaviest loads in those who had died with dementia. The reasons for this selective accumulation are still being investigated, but nanoscale particles appear to cross the blood-brain barrier in ways larger particles cannot, which may partly explain it.
Could apheresis actually clean microplastics from the human body?
Early results suggest it might, at least from the bloodstream. Researchers in Dresden reported that therapeutic apheresis, a blood-filtering technique already used clinically for other conditions, extracted material consistent with microplastic particles from human plasma. The technology exists and the clinical infrastructure is in place, but the field currently lacks the measurement tools needed to verify precisely what is being removed and in what quantities, which means robust confirmation is still some way off.
Why do ultra-processed foods keep appearing in research about brain health?
Partly because they appear to be a major delivery route for microplastic exposure, through packaging migration and manufacturing contamination, and partly because their other components seem to compound the risk independently. Large prospective studies have linked heavy ultra-processed food consumption to cognitive decline, depression, dementia, and stroke even after controlling for overall diet quality. Whether the plastic exposure and the nutritional effects are acting together or separately is a question the field is only beginning to untangle.
How do microplastics get from the gut into the brain?
Animal data suggest nanoscale particles can cross the blood-brain barrier within hours of oral exposure, acquiring a coating of proteins during transit that appears to facilitate entry. Larger microplastic fragments do not appear to make this crossing. The blood-brain barrier, which keeps most pathogens and toxins out of the central nervous system, seems not to recognize these particles as threats, which is precisely what makes the accumulation so hard to interrupt without targeted intervention.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.